One of the big challenges with cancer research is sorting out the wheat from the chaff in terms of viable targets.
If you think about it, just as we have drivers and passengers in traditional targeted therapy approaches to consider, there are also valid targets versus markers in immuno-oncology too.
We have written quite a bit about novel targeted therapy approaches of late and now it’s time to switch to IO again.
Sometimes aiming at a particular target might lead to a series of rather disappointing results in certain tumour types, yet suddenly looks much more intriguing and useful in a quite different setting.
We’ve talked about finding the sweet spot in aiming at the right cell, right compartment quite a bit on BSB, and this latest example certainly fits into this category…
To learn more from our oncology analysis and get a heads up on the latest insights and analysis pertaining to oncology R&D, subscribers can log-in or you can click to gain access to BSB Premium Content.
The start of a New Year is a good time to take stock of where we’ve come from and where we’re going in the fast-paced world of oncology new product development.
Upregulation doesn’t always mean a protein is a valid target, but in some cases it just might…
In this latest post, we’re revisiting T cell immunoglobulin and mucin domain-containing protein 3 – or TIM-3 in short – and taking a closer look at the evolving competitive landscape in this niche.
One company targeting it is Novartis, who have an anti-TIM–3 antibody MBG453 in development. In this post we have an expert interview with a scientist who is a pioneer in the emerging field of TIM-3 biology.
There’s also a review of some of the recent important scientific papers on TIM-3 biology, as well as commentary on data presented at ASH19 that we expect may feature in presentations at JPM20 next week, not to mention be the focus of future interim updates should the data turn out to show some promise in certain settings.
If you have an interest in targeting novel immune checkpoints and want to find out more about where the field is at with TIM-3, then this post is for you.
Curious to find out more about our latest oncology coverage and get a heads up on additional insights from our latest thought leader interview, analysis, and commentary? Subscribers can log-in or you can click to gain access to BSB Premium Content.
As part of our #JPM18 coverage we like to feature up and coming companies to watch out for, one of these is Syros Pharmaceuticals (NASDAQ: SYRS). In this post we take a look at what’s on the horizon for the company in 2018?
Myelofibrosis has certainly been in the news this week with Celgene acquiring Impact Biosciences for fedratinib and both Celgene and Incyte presenting their annual update at the JP Morgan Healthcare conference in San Francisco.
Yesterday at JPM, Syros and Incyte announced a new collaboration to explore myeloproliferative neoplasms (MPN):
“… The companies have entered into a target discovery, research collaboration and option agreement. Under the agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms (MPNs), and Incyte will receive options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets. Incyte will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets.”
Given the need to find new targets and potential combination agents to partner with JAK2 inhibitors such as ruxolitinib (Jakafi), this deal makes a lot of sense.
It also leaves Syros and Incyte with space to continue developing their existing pipelines in the usual fashion without any undue commitment or conflict.
Syros are a company we have been following for three years now, with several updates on BSB, including thought leader and C-suite interviews.
With new data presented at ASH and SABCS last month, it was a good time for an update on this topic, so we sat down with Dr Nancy Simonian (CEO) for a chat about where they are and where they are going with their current small molecule pipeline ahead of their presentation at JPM18.
To learn more and get a heads up on our latest thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.